Shortened Up-Dosing With 7 Injections of Subcutaneous Allergy Immunotherapy (Alutard SQ) Is Safe and Well Tolerated

J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):80-83. doi: 10.18176/jiaci.0561. Epub 2020 Jun 23.

Authors

A Horn¹, M Fernández-Rivas², H Wolf³, N Ghaussy³, T Møller Kruse⁴, K Koutromanou⁴, E Wüstenberg^{3

5}

Affiliations

¹ ENT Practice am Neckar, Drs Horn & Choudhry, Heidelberg, Germany.
² Allergy Dept, Hospital Clínico San Carlos, IdISSC, ARADyAL, Madrid, Spain.
³ Medical Department ALK-Abelló Arzneimittel GmbH, Hamburg, Germany.
⁴ ALK Global Pharmacovigilance and Clinical Development, Hørsholm, Denmark.
⁵ ENT Clinic Medical Faculty Carl-Gustav-Carus, Technical University, Dresden, Germany.

PMID: 32573456
DOI: 10.18176/jiaci.0561

No abstract available

Keywords: Adverse events; Safety; Short up-dosing; Subcutaneous allergy immunotherapy; Tolerability.

Publication types

Randomized Controlled Trial

MeSH terms

Adolescent
Adult
Aged
Child
Clinical Protocols
Desensitization, Immunologic / methods*
Female
Humans
Hypersensitivity, Immediate
Infusions, Subcutaneous
Male
Middle Aged
Plant Extracts / immunology*
Poaceae / immunology
Rhinitis, Allergic, Seasonal / immunology
Rhinitis, Allergic, Seasonal / therapy*
Treatment Outcome
Young Adult

Substances

Alutard SQ allergen
Plant Extracts